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James E. Udelson, MD,* Warren J. Manning, MD,‡§ Evan Appelbaum, MD‡§
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Objectives Our purpose was to characterize the pattern and distribution of left ventricular (LV) hypertrophy by cardiovascu-
lar magnetic resonance (CMR) to more precisely define phenotypic expression and its clinical implications in hy-
pertrophic cardiomyopathy (HCM).
Background Based on prior pathologic and 2-dimensional echocardiographic studies, HCM has been regarded as a disease
characterized by substantial LV wall thickening.
Methods Cine and late gadolinium enhancement CMR were performed in 333 consecutive HCM patients (age 43  17
years).
Results Basal anterior LV free wall and the contiguous anterior ventricular septum were the most commonly hypertro-
phied segments (n  256; 77%). LV hypertrophy was focal (involving 2 segments [12% of LV]) in 41 patients
(12%), intermediate (3 to 7 segments [13% to 49% of LV]) in 112 patients (34%), and diffuse (8 segments
[50% of LV]) in 180 patients (54%); 42 patients (13%) showed hypertrophied segments separated by regions
of normal thickness. The number of hypertrophied segments was greater in patients with LV outflow tract ob-
struction (30 mm Hg) than without (10  4 vs. 8  4 per patient; p  0.0001) and was associated with an
advanced New York Heart Association functional class (p  0.007). LV wall thickness was greater in segments
with late gadolinium enhancement than without (20  6 mm vs. 16  6 mm; p  0.001). We also identified
40 (12%) of HCM patients with segmental LV hypertrophy largely confined to the anterolateral free wall, poste-
rior septum, or apex, which was underestimated or undetected by echocardiography.
Conclusions Although diverse, patterns of LV hypertrophy are usually not extensive in HCM, involving 50% of the chamber
in about one-half the patients, and are particularly limited in extent in an important minority. Contiguous por-
tions of anterior free wall and septum constituted the predominant region of wall thickening, with implications
for clinical diagnosis. These observations support an emerging role for CMR in the contemporary evaluation of
patients with HCM. (J Am Coll Cardiol 2009;54:220–8) © 2009 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.05.006m
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Mypertrophic cardiomyopathy (HCM) has historically been
egarded as a disease characterized by hypertrophy involving
articularly substantial portions of the left ventricular (LV)
all (1–13). These perceptions regarding the morphology
f HCM were derived largely from nontomographic,
-dimensional echocardiographic imaging, as well as post-
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assachusetts; §Department of Medicine, Cardiovascular Division, Beth Israel
eaconess Medical Center, Harvard Medical School, Boston, Massachusetts; and the
Regional Referral Center for Myocardial Diseases, Azienda Ospedaliera Universita-
ia Careggi, Florence, Italy.a
Manuscript received February 13, 2009; revised manuscript received April 30,
009, accepted May 5, 2009.ortem studies (5–12,14). Volumetric cardiovascular mag-
etic resonance (CMR) offers advantages of high spatial
esolution and 3-dimensional tomographic imaging thereby
llowing for better characterization of the pattern and
istribution of LV hypertrophy in HCM (15–21). There-
ore, 50 years after the initial contemporary descriptions of
CM and its phenotypic expression, we have applied CMR
o re-examine the morphologic and clinical expression of
his complex disease in a large patient cohort.
ethods
election of patients. We prospectively studied 333 con-
ecutive HCM patients with CMR who presented to Tufts
edical Center (Boston, Massachusetts) and the Minne-
polis Heart Institute (Minneapolis, Minnesota), between
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July 14, 2009:220–8 Pattern of Hypertrophy in HCM002 and 2007. The diagnosis of HCM was based on the
MR demonstration of a hypertrophied LV (wall thickness
15 mm), associated with a nondilated cavity in the
bsence of another cardiac or systemic disease that could
roduce the magnitude of hypertrophy evident (1–3).
Echocardiographic examination was performed in all
atients within 2 weeks of CMR examination. LV outflow
ract obstruction was defined as a peak instantaneous gra-
ient of 30 mm Hg by continuous-wave Doppler echo-
ardiography under resting conditions (22). Due to the
ubstantial LV remodeling associated with “end-stage”
CM (i.e., ejection fraction 50%), these patients were
xcluded from the present cohort, as well as those patients
ho had previously undergone alcohol septal ablation or
urgical septal myectomy. Selected data from 210 study
atients have been part of previous analyses (17,23,24).
All study patients signed a statement previously approved
y the internal review boards of the respective participating
nstitutions, agreeing to the use of their medical information
or research purposes.
MR. CMR imaging was performed (Philips Gyroscan
CS-NT 1.5-T, Best, the Netherlands, and Siemens So-
ata 1.5-T, Erlangen, Germany) using steady-state, free
recession breath-hold cines in 3 long-axis planes and
equential 10-mm short-axis slices from the atrioventricular
ing to apex.
LV volumes, mass, and ejection fraction were measured
sing standard volumetric techniques (25), and analyzed
ith commercially available software (MASS, version 6.1.6,
edis, Inc., Leiden, the Netherlands). Volume and mass
easurements were indexed to body surface area. Late
adolinium enhancement (LGE) images were acquired 10
o 15 min after intravenous administration of 0.2 mmol/kg
adolinium-DTPA (Magnevist, Schering, Berlin, Ger-
any) with breath-held segmented inversion-recovery se-
uence, and acquired in the same orientations as the cine
mages. Inversion times were adjusted to null normal myo-
ardium (typically 240 to 300 ms). All tomographic short-
xis LV slices from base to apex were inspected visually to
dentify an area of completely nulled myocardium. Mean
ignal intensity (and SD) of normal myocardium was
alculated, and a threshold 6 SD exceeding the mean was
sed to define areas of LGE. Areas of artifact (i.e., blood
ool, incomplete nulling of fat, and pericardial fluid) were
xcluded from the analysis by manually adjusting the indi-
idual contours. Total volume of LGE (expressed in grams
g]) was calculated by summing the planimetered areas of
GE in all short-axis slices and was expressed as a propor-
ion of total LV myocardium (% LGE).
The short-axis LV stack was divided into 3 approximately
qual levels (basal, mid, and apical) in the longitudinal
lane. Each of these 3 levels was comprised of 3 to 4
ontiguous short-axis slices, with the total number of these
lices usually 9 to 12 per patient.
In the short-axis plane, at the basal and mid-LV levels,
ach slice was divided automatically by the MASS software snto 6 equal segments, while the
pical level slices were divided
nto 4 segments. Therefore, in
ach patient a total of 16 LV
egments were assessed accord-
ng to the standard American
eart Association segmentation
odel (26).
For each short-axis slice, the
nsertion point of right ventricu-
ar wall defined the intersection
f ventricular septum and ante-
ior free wall. In the basal and
id-LV levels, the ventricular
eptum was divided equally into anterior septum and pos-
erior septum (i.e., inferior septum) while the LV free wall
as divided equally into anterior, anterolateral, inferolateral,
nd posterior (inferior) segments. The apical level was
ivided equally into septum, anterior, lateral, and inferior.
Maximum LV wall thickness measurements in each of
he 16 segments were automatically calculated by commer-
ially available software. In the 3 LV levels (i.e., basal, mid,
pical), the greatest wall thickness measured in each of the
6 segments was recorded. The percent of the LV chamber
ypertrophied was calculated by dividing the number of LV
egments with increased wall thickness (15 mm) by the
otal number of LV segments.
Previous analyses have shown excellent interobserver and
ntraobserver agreement for similar CMR assessment of LV
all thicknesses (17,27). A patient was considered to have a
attern of noncontiguous LV hypertrophy if at least 1 LV
yocardial segment of normal wall thickness was interposed
etween 2 or more adjacent segments of hypertrophied
yocardium in either the circumferential (short-axis) or
ongitudinal (long-axis) cross-sectional plane.
tatistical analysis. Data are expressed as mean  SD.
roportions and categorical data are compared across groups
sing the Fisher exact test. Confidence intervals for propor-
ions are calculated using the binomial equation. Continu-
us data are compared across groups using the Wilcoxon
ank sum test. Analyses of per-segment correlations be-
ween maximal segmental wall thickness and segmental
GE are adjusted for shared, within-patient variance using
ixed-effects models. Other analyses of the same per-
egment measures are summarized per patient before anal-
sis with no other adjustment for within-patient effects.
tatistical analyses were performed using Stata (version 10,
tata Corp., College Station, Texas).
esults
atient characteristics. Clinical and demographic charac-
eristics of the 333 study patients are summarized in Table 1.
ean age at evaluation was 43  17 years (range 8 to 86
ears); 240 patients (72%) were men. At the time of CMR
Abbreviations
and Acronyms
CMR  cardiovascular
magnetic resonance
HCM  hypertrophic
cardiomyopathy
LGE  late gadolinium
enhancement
LV  left ventricle/
ventricular
NYHA  New York Heart
Associationtudy, 217 patients (65%) were asymptomatic in New York
H
h
p
N
w
r
L
m
m
(
h
m
i
p
i
p
o
s
(
5
H
L
n
i
0
g
d
r
p
0
L
L
a
a
o
b
p
p
(
C
l
v
g
t
3
a
p
s
t
s
m
e
t
a
C
V
me; HC
A
222 Maron et al. JACC Vol. 54, No. 3, 2009
Pattern of Hypertrophy in HCM July 14, 2009:220–8eart Association (NYHA) functional class I, 75 (23%)
ad mild symptoms in NYHA functional class II, and 41
atients (12%) had severe heart failure symptoms in
YHA functional class III or IV. LV ejection fraction
as 72  7%. LV outflow obstruction 30 mm Hg under
esting conditions was present in 77 patients (23%).
V wall thickness. For the overall study cohort, the
aximal LV wall thickness was 22  5 mm (range 15 to 50
m) with a total of 2,741 LV segments hypertrophied
average per patient 8  4). Distribution and extent of LV
ypertrophy was diverse (Fig. 1): focal involving 2 seg-
ents (12% of LV) in 41 (12%) patients, moderate
nvolving 3 to 7 segments (13% to 49% of LV) in 112 (34%)
atients, and diffuse involving 8 segments (50% of LV)
n 180 (54%) patients (Table 1, Fig. 2). Therefore, in 153
atients (46%) hypertrophy was present in 50% of the
verall LV chamber.
Among the 333 study patients, the basal anterior septum
howed the highest average maximal LV wall thickness
20  5 mm) followed by the basal anterior free wall (19 
mm) and midposterior septum (19  5 mm) (Fig. 3).
owever, average wall thickness was 15 mm in 9 other
V segments (56%).
Maximal LV wall thickness was directly related to the
umber of hypertrophied segments: focal (17  1 mm),
ntermediate (20  4 mm), and diffuse (25  5 mm; p 
.0001). Total LV mass index was 68  13 g/m2, 82  17
/m2, and 120  32 g/m2 in patients with focal, interme-
iate, and diffuse hypertrophy, respectively. A significant
linical Characteristics and CMR Findings in 333 Patients With HCTable 1 Clinical Characteristics and CMR Findings in 333 Pati
All Patients (n  333) Focal*
Age (yrs) 43 17 40
Men 240 (72%) 25 (
Number of hypertrophied segments 8 4 1.7
Maximal LV wall thickness (mm) 22 5 17
LV obstruction at rest (30 mm) 77 (23%) 4 (
NYHA functional class
I 217 (65%) 29 (
II 75 (23%) 8 (
III 38 (11%) 3 (
IV 3 (1%) 0 (
Atrial fibrillation 37 (11%) 3 (
Systemic hypertension 78 (23%) 5 (
LV mass (g) 201 79 130
LV mass index (g/m2) 101 34 68
ESV (ml) 46 18 48
EDV (ml) 165 43 161
Stroke volume (ml) 119 3 113
Ejection fraction (%) 72 7 71
LGE present 128 (45%) 7 (
LGE (g) 12 17 7
% LGE 9 9 12
alues are mean  SD or n (%). *Number of hypertrophied left ventricular (LV) segments: focal (1
CMR cardiovascular magnetic resonance; EDV end-diastolic volume; ESV end-systolic volu
ssociation.elationship was evident between the number of hypertro- ahied LV segments and LV mass index (r2  0.83; p 
.0001).
ocation and distribution of LV hypertrophy. Increased
V wall thickness was most commonly located in the
nterior free wall (n  266; 80%) and contiguous basal
nterior ventricular septum (n  286; 86%) (Fig. 4). In 256
f the 333 study patients (77%), hypertrophy was present in
oth these segments (i.e., 1 o’clock position in the short-axis
lane) (Fig. 5A). Hypertrophy was commonly present in the
osterior portion of septum, usually at the mid-LV level
n  253; 76%) (Fig. 4).
Finally, among 40 (12%) of the 333 HCM study patients,
MR identified hypertrophy completely (or predominately)
imited to the anterolateral free wall, posterior portion of
entricular septum, or LV apex, in whom the echocardio-
ram markedly underestimated (or did not detect) hyper-
rophy in those same regions (Fig. 6). In 5 patients (1.5% of
33), LV hypertrophy was confined to the anterior or
nterolateral LV free wall (Fig. 5B).
Of the 333 patients, 42 (13%) showed a noncontiguous
attern of LV wall thickening involving 2 hypertrophied
egments (Fig. 7). The most common locations for noncon-
iguous hypertrophy were combinations of basal anterior
eptum and apical lateral wall or basal anterior septum and
id-LV posterior septum. There were no significant differ-
nces evident between patients with a noncontiguous pat-
ern of LV hypertrophy and other patients, with respect to
ge (p  0.5), sex (male, p  0.5), LV outflow obstruction
ccording to Number of Hypertrophied LV SegmentsWith HCM According to Number of Hypertrophied LV Segments
1) Intermediate* (n  112) Diffuse* (n  180) p Value
4 17 45 16 0.14
76 (68%) 139 (77%) 0.05
5.0 1.4 11.7 2.7 0.0001
20 4 25 5 0.0001
20 (18%) 53 (29%) 0.007
81 (72%) 107 (59%) 0.13
21 (19%) 46 (26%)
9 (8%) 26 (14%)
1 (1%) 2 (1%)
8 (7%) 26 (14%) 0.11
23 (21%) 50 (28%) 0.07
155 40 247 76 0.0001
82 17 120 32 0.0001
45 20 46 17 0.39
159 43 169 43 0.13
114 29 123 33 0.05
72 7 73 7 0.26
32 (32%) 89 (57%) 0.0001
10 13 17 20 0.5
9 11 9 9 0.6
intermediate (3 to 7), diffuse (8).
M hypertrophic cardiomyopathy; LGE late gadolinium enhancement; NYHA New York HeartM Aents
(n  4
18
61%)
0.5
1
10%)
73%)
20%)
8%)
0%)
7 %)
12%)
32
13
18
42
31
7
23%)
9
11
to 2),t rest (p  0.15), or NYHA functional class (p  0.24).
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July 14, 2009:220–8 Pattern of Hypertrophy in HCMelation of LV hypertrophy to LGE. LV wall thickness
as greater in segments with LGE compared with segments
ithout LGE (20 6 mm vs. 16 6 mm; p 0.001) (Fig. 8).
n addition, maximum LV wall thickness and total LV mass
ndex were greater in patients with LGE compared with those
ithout LGE (24  5 mm vs. 21  4 mm; p  0.0001 and
10 g/m2 vs. 94 g/m2; p 0.002, respectively). Also, LGE was
ore common in patients with diffuse hypertrophy (89 of 151;
9%), than with intermediate (31 of 95; 33%) or focal hyper-
rophy (7 of 31; 23%; p  0.001).
The number of hypertrophied LV segments with LGE
ased on wall thickness tertiles was 15 mm, 23 of 207
11%); 16 to 20 mm, 217 of 1,444 (15%); 21 to 25 mm, 291
f 1,615 (18%); 26 to 30 mm, 137 of 1,807 (17%); and 30
m, 72 of 359 (20%) (p  0.01). However, % LGE was
nrelated to maximal LV wall thickness (r  0.03;
 0.7) or the number of hypertrophied segments (r 
0.03; p  0.7) (Table 1).
elation of LV hypertrophy to clinical and demographic
ariables. The number of hypertrophied LV segments was
reater in patients with LV outflow tract obstruction (30
m Hg at rest) compared with nonobstructed patients
10  4 vs. 8  4; p  0.001). In addition, patients with
Figure 1 A Diverse Pattern of LV Hypertrophy in HCM
A spectrum of patterns of left ventricular (LV) wall thickening constitutes the phen
nance end-diastolic short-axis and long-axis images demonstrate (A) hypertrophy i
hypertrophy sharply confined to the basal anterior septum (arrows); (C) hypertroph
FW (*); contiguous anterior septum is normal thickness; (E) massive asymmetric
the posterior septum and LV FW; and (F) diffuse hypertrophy involving most of thedvanced NYHA functional class III/IV heart failure symp- Coms had a greater number of hypertrophied segments (n 
1) compared with class II minimally symptomatic (n  9)
r class I asymptomatic (n  8) (p  0.007) patients.
owever, the extent of hypertrophy was unrelated to age
p  0.14), sex (p  0.05), atrial fibrillation (p  0.11), and
jection fraction (p  0.26).
iscussion
ince its initial description 50 years ago, the phenotypic
xpression of HCM has often been characterized as an
xample of extensive LV hypertrophy, albeit with a
iversity of patterns (1–12). This perception emanates
rom earlier autopsy observations in which LV wall
hickness measurements made in rigor mortis were equiv-
lent to those in systole (8,14), and subsequently from
tudies with 2-dimensional echocardiography, an imag-
ng technique that depends on nontomographic (and
ften oblique) cross-sectional planes, and consequently
oes not image the entire LV chamber.
CMR is an important addition to the imaging armamen-
arium for HCM (15,18,19,21,27,28). Indeed, as a compre-
ensive tomographic technique with high spatial resolution,
expression of hypertrophic cardiomyopathy (HCM). Cardiovascular magnetic reso-
g the ventricular septum (VS), sparing the LV free wall (FW); (B) focal area of
e LV apex (*); (D) segmental hypertrophy predominantly of the anterolateral LV
rophy of the anterior VS (wall thickness 48 mm) with sparing of hypertrophy in
m and FW. RV  right ventricle.otypic
nvolvin
y of th
hypert
septuMR provides complete reconstruction of the LV chamber
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Pattern of Hypertrophy in HCM July 14, 2009:220–8nd a more precise definition of the distribution of hyper-
rophy (16–18,20,29,30). Therefore, to this purpose, we
ave assembled here a particularly large consecutive cohort
f patients with HCM imaged with CMR to permit a
etailed assessment of the diverse and complex phenotypic
xpression in this disease.
In this cohort analysis, we found that about one-half of
ur HCM patients had areas of hypertrophy that were
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Figure 2 Prevalence of Hypertrophied Segments
Prevalence of focal (1 to 2 hypertrophied segments), intermediate (3 to 7 seg-
ments), and diffuse left ventricular hypertrophy (8 to 16 segments) within the
cohort of 333 patients with hypertrophic cardiomyopathy.
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Figure 3 Average LV Wall Thickness per SegmentDistribution of mean left ventricular (LV) wall thicknesses in 16 segments, according to the Aonfined to 50% of the overall LV chamber, including a
ubstantial minority with particularly focal or regional areas
f increased LV wall thickness. In fact, over 10% of the
tudy patients showed only 1 or 2 hypertrophied LV
egments, a phenotypic expression that would not be ex-
ected to result in an increased calculated LV mass (24).
herefore, these results are inconsistent with the still
opular notion that extensive hypertrophy represents the
haracteristic phenotypic expression of HCM or is a re-
uirement for clinical diagnosis (4,5,7–10,12,13,24). Fi-
ally, among this large cohort of HCM patients, over
ne-half of the 16 LV segments had an average maximal
all thickness of 15 mm. This finding also raises impor-
ant considerations with regard to the relation between the
CM genetic substrate (and disease-causing mutations)
nd phenotypic expression. In this regard, the observation
hat sarcomere protein mutations responsible for HCM (31)
re not associated with hypertrophy distributed throughout
ost or all of the LV wall suggests that other factors, such
s modifier genes or environmental triggers, may be impor-
ant contributors to modification of the HCM phenotype.
A related but unexpected finding with CMR was that the
redominant area of LV wall thickening in HCM involved
he basal anterior free wall in continuity with the anterior
entricular septum (“1 o’clock” in the short-axis plane),
ather than more centrally in the “12 o’clock” position
n the anterior septum, as traditionally regarded with
-dimensional echocardiography (6,7). Indeed, the present
bservation that the anterior free wall is a particularly
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July 14, 2009:220–8 Pattern of Hypertrophy in HCMommon, and frequently the predominant site of wall
hickening within the LV, has not previously been appre-
iated with nontomographic imaging modalities. Further-
ore, we identified an important minority of HCM pa-
ients in whom segmental LV hypertrophy was largely
onfined to the anterolateral wall, posterior septum, or apex
nd in whom the echocardiogram dramatically underesti-
ated (or did not detect) hypertrophy in those same
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Figure 4 Frequency of LV Hypertrophy by Segment
Frequency of hypertrophied LV segments according to the 16-segment American H
Hypertrophy is defined as maximal wall thickness 15 mm in any given segment.
Figure 5 The Most Common Regions of LV Hypertrophy
The basal anterior free wall and contiguous portion of the anterior ventricular sept
phic cardiomyopathy. (A) Cardiovascular magnetic resonance end-diastolic short-a
the basal anterior free wall and a portion of the contiguous anterior septum (arrow
42-year-old man with hypertrophic cardiomyopathy showing a focal area of hypertro
ventricle.egions. Only CMR was capable of identifying the extent of
ypertrophy and/or the diagnostic morphology (29,30).
Taken together, these observations imply that absolute
V wall thickness may have been previously underestimated
n many HCM patients, as the true epicardial border of the
V free wall is often not visualized accurately with
-dimensional echocardiography, ultimately supporting the
ole for CMR in providing more comprehensive and precise
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resent the most common area of left ventricular (LV) wall thickening in hypertro-
ge from a 33-year-old hypertrophic cardiomyopathy patient with hypertrophy of
aring other portions of the LV wall. (B) End-diastolic short-axis image from a
nfined to the basal anterior free wall measuring 22 mm (*). RV  rightnt
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Pattern of Hypertrophy in HCM July 14, 2009:220–8iagnostic imaging in HCM. Of note, these findings not
nly have important implications for noninvasive HCM
iagnosis, but also for planning proper operative manage-
ent strategies for surgical septal myectomy candidates by
ecognizing the need to adjust the muscular resection to
arget the most hypertrophied portion of the anterior LV,
hereby assuring optimal reduction in LV outflow gradient
hile avoiding iatrogenic ventricular septal defect (32–35).
Another novel finding in assessing our HCM cohort with
MR was the noncontiguous distribution of segmental
reas of LV wall thickening present in almost 15% of
atients. This morphologic pattern consisted of hypertro-
hied segments separated by regions of nonhypertrophied
yocardium, creating abrupt changes in wall thickness in
djacent portions of the wall and a “lumpy” hypertrophic
attern. This distribution of LV hypertrophy would seem
ost consistent with a genetically determined cardiomyo-
Figure 6 LV Hypertrophy Recognized by CMR But Not Reliably
(A) Four-chamber image showing hypertrophy confined to the LV apex (*); (B) Mid
of the ventricular septum (*); (C) Basal short-axis image demonstrating hypertrophy v
nance; other abbreviations as in Figure 5.
Figure 7 Noncontiguous Areas of LV Hypertrophy
(A) End-diastolic short-axis cardiovascular magnetic resonance image from a 45-ye
posterior (inferior) LV wall (*), separated by regions of normal LV thickness (arrow
33-year-old woman showing another noncontiguous pattern of LV hypertrophy in wh
tum (*) separated by areas of normal LV wall thickness (arrows). Abbreviations aathic process (such as HCM) rather than forms of hyper-
rophy secondary to pressure overload (such as systemic
ypertension), and in selected patients could possibly con-
ribute to resolution of the differential diagnosis between
rimary (genetic) and secondary hypertrophy, when this
istinction is otherwise ambiguous (36).
LGE imaging provides a novel, noninvasive method for
n vivo identification and quantification of myocardial fibro-
is, which we (17,23) and others (15,19–21,37) have previ-
usly applied to other HCM patient groups. Areas of LGE
roved to be most common in those segments of the LV
ith the greatest magnitude of wall thickening (15,19). This
bserved relation between LV wall thickness and the pres-
nce of LGE was largely unanticipated. We would have
xpected that LGE, presumably representing the conse-
uences of longstanding microvascular ischemia, and result-
ng in myocyte death and ultimately replacement fibrosis as
2-Dimensional Echocardiography
ort-axis image showing increased wall thickness localized to the posterior portion
limited to the anterolateral free wall (*). CMR  cardiovascular magnetic reso-
man demonstrating segmental LV hypertrophy of the basal anterior septum and
) End-diastolic short-axis cardiovascular magnetic resonance image from a
ere is increased thickness of the inferior (posterior) free wall and anterior sep-
ure 5.With
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July 14, 2009:220–8 Pattern of Hypertrophy in HCMrepair process, to be evident predominantly in thinner
egments of LV and associated with abnormalities of wall
otion. Whether our observations and those of others
15,19,21,38) in this regard suggest that some LGE evident
n HCM patients does not truly represent myocardial
carring is unresolved, but does raise the importance of
urther studies in this disease correlating LGE (by CMR)
ith histopathology (38).
In this cross-sectional analysis, we identified a significant
elation between extent of LV hypertrophy (i.e., the number
f hypertrophied segments) and both the presence of LV
utflow obstruction and more advanced heart failure func-
ional class. This association between greater magnitude of
V hypertrophy and limiting symptoms is consistent with
he report that marked CMR-calculated LV mass was
ssociated with a less favorable clinical outcome over a
elatively short follow-up period (24), although different
rom that reported previously with 2-dimensional echocar-
iography (6). In addition, the finding that LV outflow
bstruction (at rest) is associated with more substantial LV
ypertrophy is consistent with previous observations that
CM patients with outflow obstruction show greater LV
ass than patients with the nonobstructive form, suggesting
hat longstanding exposure to increased LV systolic pres-
ures may promote secondary hypertrophy due to pressure
verload (6,24,28).
onclusions
ontemporary CMR provides a measure of clarity to the
orphology of HCM and specifically the distribution and
atterns of LV hypertrophy, which characterize the disease
Figure 8 LGE in HCM
Four-chamber long-axis contrast-enhanced cardiovascular magnetic resonance
image in an asymptomatic 26-year-old woman with hypertrophic cardiomyopathy
(HCM) demonstrating an area of late gadolinium enhancement (LGE) in the
midmyocardial region of maximal anterior septal thickness (arrows). LGE is
absent in the remainder of LV wall (*). LA  left atrium; RA  right atrium;
other abbreviations as in Figure 3.henotype. While diverse, it is notable that the structuralxpression of the cardiomyopathic process in HCM is often
egmental and nondiffuse, and may also demonstrate non-
ontiguous patterns of wall thickness. Recognition that the
nterior LV free wall is more commonly and often predom-
nantly involved in the hypertrophic process than previously
egarded (and can also be the sole area of wall thickening)
epresents an important principle for the noninvasive diag-
osis of HCM. Taken together, these observations under-
core an important role for CMR in the contemporary
ssessment of patients with HCM.
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